InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,816.37
(
0.63%
)
US TECH 100
19,722.40
(
0.10%
)
Dow Jones
42,752.62
(
0.70%
)
Brent Oil
78.99
(
-0.09%
)
Bitcoin
61,795.57
(
2.53%
)
Post# of 253342
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120557
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rfj1862 post# 51988

Thursday, 09/06/2007 11:59:35 PM

Thursday, September 06, 2007 11:59:35 PM

Post# of 253342
>…no physician would take a patient who was doing poorly on atorvastatin and switch them to simvastatin in the hopes that they would respond better to simvastatin.<

That’s a reasonable premise, IMO. The plausible options for switching such patients in the hopes of obtaining better efficacy are: i) Crestor, and ii) Vytorin.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up